1. Home
  2. NTLA vs CBL Comparison

NTLA vs CBL Comparison

Compare NTLA & CBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$17.38

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo CBL & Associates Properties Inc.

CBL

CBL & Associates Properties Inc.

HOLD

Current Price

$52.66

Market Cap

1.5B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
CBL
Founded
2014
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2016
1995

Fundamental Metrics

Financial Performance
Metric
NTLA
CBL
Price
$17.38
$52.66
Analyst Decision
Buy
Strong Buy
Analyst Count
23
1
Target Price
$20.02
$45.00
AVG Volume (30 Days)
6.7M
312.2K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
4.00%
EPS Growth
27.43
132.09
EPS
N/A
1.48
Revenue
$67,671,000.00
$578,373,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$62.75
N/A
P/E Ratio
N/A
$37.35
Revenue Growth
16.92
12.18
52 Week Low
$7.95
$25.53
52 Week High
$28.24
$55.41

Technical Indicators

Market Signals
Indicator
NTLA
CBL
Relative Strength Index (RSI) 69.19 60.43
Support Level $11.73 $46.65
Resistance Level $27.61 N/A
Average True Range (ATR) 1.21 1.63
MACD 0.28 0.33
Stochastic Oscillator 84.38 64.88

Price Performance

Historical Comparison
NTLA
CBL

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About CBL CBL & Associates Properties Inc.

CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.

Share on Social Networks: